Australia's most trusted
source of pharma news
Thursday, 05 March 2026
Posted 5 March 2026 AM
Eli Lilly has just completed two pilot studies using accredited AI-powered programs which can be tailored to the individual needs of the HCP.
Developed by Med-ed.ai, the programs are guard-railed to avoid false information being presented and are bespoke, aligning with a doctor's knowledge on a particular subject.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.